



Supplementary Fig. 1. Flow diagram of the study population. GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycosylated hemoglobin; CKD, chronic kidney disease; SU, sulfonylurea; MET, metformin; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; TZD, thiazolidinedione.